Editas Medicine, Inc. (EDIT)

In April 2025, Editas Medicine's market capitalization was around $85.46 million USD, and the company announced a significant workforce reduction. In March 2025, Editas Medicine reported a significant net loss for 2024 and the discontinuation of the reni-cel program, but also a strong cash position. In the second quarter of 2025, Editas Medicine reported revenue of slightly under $3.6 million and a net loss of approximately $53 million, with a 34% increase in share price in mid-August 2025. In October 2025, Editas Medicine presented in vivo preclinical proof-of-concept data for EDIT-401, but the stock price experienced a decline of -12.63% on October 27, 2025.

There is no explicit mention or indication of demand seasonality for Editas Medicine's products or services. The demand for its potential future treatments would likely be driven by medical need and regulatory approvals rather than seasonal patterns.

Editas Medicine is a clinical-stage biotechnology company focused on developing genomic medicines using CRISPR gene editing technology, utilizing CRISPR/Cas9 and CRISPR/Cas12a systems to develop therapies for serious diseases. Its pipeline includes experimental medicines like EDIT-301 for hemoglobinopathies and EDIT-401 for reducing LDL cholesterol levels, along with collaborations for cellular therapy assets. The company discontinued internal investments in inherited retinal disease programs in early 2023 and the reni-cel program in December 2024, leading to restructuring and workforce reduction.

Editas Medicine's corporate headquarters is in Cambridge, Massachusetts, with facilities in Boulder, Colorado, supporting research programs and technical operations. While its direct office presence is U.S.-based, its reach is global through clinical trials and collaborations.

Editas Medicine is recognized as a pioneer in gene editing technology, holding exclusive rights to CRISPR. The company has a strong brand and deep expertise in both Cas9 and Cas12a CRISPR technology. However, the discontinuation of the reni-cel program in December 2024 was a significant blow to its pipeline and negatively impacted market sentiment. The company's financial challenges have also affected its reputation and investor confidence. Analysts have mixed ratings, with a consensus "Hold" rating, reflecting uncertainty.

The ownership structure of Editas Medicine is a mix of institutional, retail, and individual investors. Individual investors hold the largest portion, around 53% of the company's shares. Institutional investors collectively own a significant portion, with approximately 47% to 71.90% of the stock. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., Geode Capital Management, Llc, Millennium Management Llc, State Street Corp, and Morgan Stanley. Kevin P. Starr is noted as a significant individual shareholder, owning 4.34% of the company's shares. Insiders own under 1% of the company, and there have been recent insider sales.